[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"covid-19-recurrent\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:covid-19-recurrent":62},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100557921","efficacy-of-non-invasive-neuromodulation-treatments-for-covid-19-sequelae-100557921",false,"NCT06544395","Efficacy of Non-invasive Neuromodulation Treatments for COVID-19 Sequelae","Efficacy of Non-invasive Neuromodulation Treatments for Post-COVID-19 Sequelae in Patients With Musculoskeletal, Respiratory and Neurological Conditions Due to Impaired Taste and Smell.","COVID-19","Inclusion Criteria:\n\n* Patients between the ages of 18 and 60.\n* Patients with a positive diagnosis of COVID-19.\n* Patients with post-COVID-19 sequelae with musculoskeletal, respiratory or neurological symptoms due to taste or smell lasting at least 30 days, with no history of respiratory and\u002For neurological and\u002For musculoskeletal diseases.\n* Patients who signed the informed consent.\n\nExclusion criteria:\n\n* Patients aged before 18 years and after 60 years.\n* Healthy people with no history of neurological, neurological and\u002For respiratory and\u002For musculoskeletal diseases\n* Patients with secondary diseases that could directly affect the systems to be evaluated who were not diagnosed positive for COVID-19.","ALL","18 Years","60 Years",{"count":21,"type":22},104,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to demonstrate the effectiveness of non-invasive Neuromodulation as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of Covid-19. It will also estimate the impact of non-invasive neuromodulation treatment on the functionality and quality of life of patients with COVID-19 sequelae.The main question it aim to answer is:\n\n\\- Is non-invasive neuromodulation effective as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of Covid-19.\n\nResearchers will compare non-invasive neuromodulation to a placebo (treatment with the machine turned off).\n\nParticipants will:\n\n* Be evaluated before starting treatment.\n* Be evaluated 3 weeks after.\n* Be evaluated at 5 weeks, or 15 sessions or completion of treatment.\n* Be evaluated 6 weeks after finishing the treatment or 11 weeks after starting treatment.",[28],"Covid-19 Recurrent",[30,31,32],"Covid-19","Non Invasive Neuromodulation","Smell","NOT_YET_RECRUITING","2025-09-17",{"date":36,"type":37},"2025-09-18","ACTUAL",{"date":39,"type":22},"2026-01-01",{"date":41,"type":22},"2026-12-30",{"name":43,"class":44},"Clinica Gema Leon","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100549544","sars-cov-2-specific-antibody-responses-and-impact-for-covid-19-disease-in-ethiopia-100549544","NCT06435403","SARS-CoV-2 Specific Antibody Responses and Impact for COVID-19 Disease in Ethiopia","SARS-CoV-2 Specific Antibody Responses and Impact for COVID-19 Disease in Health Care Worker and Community Members From Ethiopian Related to Natural SARS CoV-2 Infection and COVID-19 Vaccination","CoVICIS","Inclusion criteria:\n\n1. Adults, 18 years of above\n2. Provision of oral as well as written informed consent\n3. Available estimation of the period or the time-point when SARS-CoV-2 infection occurred (e.g. confirmed or highly suspected COVID-19 disease, SARS-CoV-2 anti-nucleocapsid seroconversion) (only applicable for participants included in group 1 and 2).\n4. Employed\u002Fworking in hospital (medical doctors, nurses\u002Fmidwives, students, auxiliary personnel such as cleaner, runner, social worker) for HCW\n5. Willingness to provide blood samples by venipuncture for serology and immunological characterization\n6. Willingness to provide health information, report medical events and to performed SARS-CoV-2 diagnostics (swabs for PCR) in the case of suspected COVID-19 disease\n\nExclusion criteria:\n\n1. Prisoners\n2. Mentally disturbed persons\n3. Persons for whom study participation will induce an unacceptable risk or burden as judged by the investigator (e.g. seriously sick persons)",true,{"count":56,"type":22},1000,"OBSERVATIONAL","In this study we aim to characterize SARS CoV-2 strain specific immune response (SARS-CoV-2 Spike IgG) in health care workers and general populations at the Jimma Medical Center and the St. Paul Hospital in Addis Ababa in association to clinical immune protection and Covid-19 disease. Participants, stratified by SARS-CoV-2 infection and vaccination status, will be followed at 3-month intervals for a maximum of 2 years. Prevalence, incidence, and dynamics of SARS-CoV-2 specific antibodies as well as clinical assessments especially related to COVID-19 breakthrough disease in previously exposed\u002Fvaccinated participants will be performed. From a subset of selected participant blood sample, more in depth immunological analysis will be performed that include virus culture-based neutralization assays, antibody avidity assays, SARS-CoV-2 specific antibody epitope recognition using peptide arrays, and T-cell immunity assays (IGRA).\n\nWe also plan to analyze and model cost-effectiveness considerations related to adapted COVID-19 vaccine strategies, specifically if SARS-CoV-2 the costs for routine sero-diagnosis in high SARS-CoV-2 prevalent population prior to vaccination will impact the decision to vaccinate (no vaccination for low-risk populations or reduced vaccine dosing) and is cost-efficient. The study is largely exploratory, providing deeper insights in SARS-CoV-2 specific immune responses and interaction with SARS-CoV-2 viral variants.",[60,61,62],"SARS CoV 2 Infection","COVID-19 Breakthrough","COVID-19 Recurrent",[15,64,65,66,67],"Seroepidemiologic Studies","Longitudinal Studies","Ethiopia \u002F epidemiology","SARS-CoV-2","RECRUITING","2024-07-08",{"date":71,"type":37},"2024-07-09",{"date":73,"type":37},"2022-11-10",{"date":75,"type":22},"2025-02-28",{"name":77,"class":44},"Michael Hoelscher",2,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":45},"100528996","covid-19-vaccine-effectiveness-against-recurrent-infection-among-lung-cancer-patients-and-biomarker-research-100528996","NCT06168032","COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research","Efficacy of COVID-19 Booster-Dose Vaccine for Re-infection Precaution and Dynamics of Specific Serum Antibodies in the Management of Lung Cancer Patients With Systemic Anti-cancer Treatment","Inclusion Criteria:\n\n1. Patients who agree to participate in the trial and sign the informed consents.\n2. Male or female, ≥18 years old.\n3. Diagnosed of lung carcinoma by histological and cytological examinations.\n4. Undergoing systemic anti-tumor treatments including chemotherapy, immunotherapy, chemoimmunotherapy and targeted therapy.\n5. Recorded history of COVID19 infection.\n6. Sufficiently functional organs.\n7. Eastern Cooperative Oncology Group performance score (PS) ranging from 0 to 2.\n\nExclusion Criteria:\n\n1. Life expectance less than 3 months.\n2. Less than 3 months since last confirmed COVID-19 infection.\n3. Patients unable to return the hospital for follow-up.\n4. Patients allergic to COVID-19 vaccine.\n5. Patients with histories of severe treatment-related adverse events graded 3rd or higher, including those caused by antitumor therapies or immunization except recoverable granulocytopenia.",{"count":87,"type":22},1224,[25],"A prospective, open-label and parallel non-randomized control trial and biomarker research study is intended to compare incidence of repeated COVID-19 infection, severe pneumonitis and mortality between lung cancer patients undergoing systemic antitumor therapies who get vaccinated with 1 booster dose(majorly against XBB) and those who refuse. Meanwhile, a biomarker research is designed to monitor serum level dynamics of specific antibodies against COVID-19,analyze its correlation with incidence of breakthrough infection and further explore optimal periods for vaccination.",[62,91,92,93,94,95],"Lung Cancer","Vaccination","Antibody","Chemotherapy","Immune Checkpoint Inhibitor","2023-12-11",{"date":98,"type":37},"2023-12-13",{"date":100,"type":22},"2023-12-08",{"date":102,"type":22},"2026-12-08",{"name":104,"class":44},"Peking Union Medical College Hospital"]